-
Tissue bridge widths and outcome after spinal cord injury Lancet Neurol. (IF 46.5) Pub Date : 2024-06-27 James Guest
-
Effects of spaceflight on the brain Lancet Neurol. (IF 46.5) Pub Date : 2024-06-27 Prof Rachael D Seidler PhD, Prof Xiao Wen Mao MD, Grant D Tays MS, Tianyi Wang MS, Prof Peter zu Eulenburg MD PhD
The number of long duration human spaceflights has increased substantially over the past 15 years, leading to the discovery of numerous effects on the CNS. Microgravity results in headward fluid shifts, ventricular expansion, an upward shift of the brain within the skull, and remodelling of grey and white matter. The fluid changes are correlated with changes to perivascular space and spaceflight associated
-
Prognostic value of tissue bridges in cervical spinal cord injury: a longitudinal, multicentre, retrospective cohort study Lancet Neurol. (IF 46.5) Pub Date : 2024-06-27 Dario Pfyffer PhD, Andrew C Smith PhD, Kenneth A Weber II PhD, Andreas Grillhoesl MD, Orpheus Mach MA, Christina Draganich DO, Jeffrey C Berliner DO, Candace Tefertiller PhD, Iris Leister PhD, Doris Maier MD, Prof Jan M Schwab MD, Prof Alan Thompson, Prof Armin Curt MD, Prof Patrick Freund MD
The accuracy of prognostication in patients with cervical spinal cord injury (SCI) needs to be improved. We aimed to explore the prognostic value of preserved spinal tissue bridges—injury-spared neural tissue adjacent to the lesion—for prediction of sensorimotor recovery in a large, multicentre cohort of people with SCI. For this longitudinal study, we included patients with acute cervical SCI (vertebrae
-
Bailout angioplasty or stenting for large vessel occlusion Lancet Neurol. (IF 46.5) Pub Date : 2024-06-21 Joanna M Roy, Stavropoula Tjoumakaris
-
Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial Lancet Neurol. (IF 46.5) Pub Date : 2024-06-21 Prof Feng Gao MD, Xu Tong MD, Baixue Jia MD, Prof Ming Wei MD, Prof Yuesong Pan PhD, Ming Yang MD, Dapeng Sun MD, Prof Thanh N Nguyen MD, Prof Zeguang Ren, Francis Demiraj MD, Xiaoxi Yao MD, Chenghua Xu MD, Guangxiong Yuan MD, Yue Wan MD, Jianjun Tang MD, Jing Wang MD, Yuanfei Jiang MD, Chaobin Wang MD, Prof Xiang Luo MD, Haihua Yang MD, Ruile Shen MD, Zhilin Wu MD, Zhengzhou Yuan MD, Dongjun Wan MD
Unsuccessful recanalisation or reocclusion after thrombectomy is associated with poor outcomes in patients with large vessel occlusion (LVO) acute ischaemic stroke (LVO-AIS). Bailout angioplasty or stenting (BAOS) could represent a promising treatment for these patients. We conducted a randomised controlled trial with the aim to investigate the safety and efficacy of BAOS following thrombectomy in
-
Tenecteplase versus alteplase in stroke thrombolysis: the last piece of the puzzle? Lancet Neurol. (IF 46.5) Pub Date : 2024-06-13 Kazunori Toyoda
-
Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4·5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial Lancet Neurol. (IF 46.5) Pub Date : 2024-06-13 Prof Mark W Parsons PhD, Vignan Yogendrakumar PhD, Prof Leonid Churilov PhD, Carlos Garcia-Esperon PhD, Prof Bruce C V Campbell PhD, Michelle L Russell RN, Gagan Sharma MCA, Chushuang Chen PhD, Longting Lin PhD, Beng Lim Chew MD, Felix C Ng PhD, Akshay Deepak MD, Philip M C Choi MBChB, Prof Timothy J Kleinig PhD, Dennis J Cordato PhD, Teddy Y Wu PhD, John N Fink MBChB, Prof Henry Ma PhD, Prof Thanh
Intravenous tenecteplase increases reperfusion in patients with salvageable brain tissue on perfusion imaging and might have advantages over alteplase as a thrombolytic for ischaemic stroke. We aimed to assess the non-inferiority of tenecteplase versus alteplase on clinical outcomes in patients selected by use of perfusion imaging. This international, multicentre, open-label, parallel-group, randomised
-
Management of subdural haematoma: optimising drainage Lancet Neurol. (IF 46.5) Pub Date : 2024-06-12 Amjad Elmashala, Jonathan Rosand
-
Optimal drainage time after evacuation of chronic subdural haematoma (DRAIN TIME 2): a multicentre, randomised, multiarm and multistage non-inferiority trial in Denmark Lancet Neurol. (IF 46.5) Pub Date : 2024-06-12 Mads Hjortdal Grønhøj PhD, Thorbjørn Søren Rønn Jensen MD, Rares Miscov MD, Ann Kathrine Sindby MD, Birgit Debrabant Dr rer nat, Torben Hundsholt MD, Prof Carsten Reidies Bjarkam DMSc, Bo Bergholt MD, Kåre Fugleholm DMSc, Prof Frantz Rom Poulsen PhD, DACSUHS group
Postoperative drainage after surgical evacuation of chronic subdural haematoma reduces the risk of recurrence, but the optimum drainage time is uncertain. We aimed to investigate the shortest possible drainage time without increasing the haematoma recurrence rate. We conducted a randomised, multi-arm and multistage non-inferiority trial at four neurosurgical centres in Denmark. We enrolled adult patients
-
Caring for the carers: the power of personal stories Lancet Neurol. (IF 46.5) Pub Date : 2024-06-06 Udani Samarasekera
-
Amyotrophic lateral sclerosis: a lesson in translation Lancet Neurol. (IF 46.5) Pub Date : 2024-05-20 Orla Hardiman
-
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial Lancet Neurol. (IF 46.5) Pub Date : 2024-05-20 Prof Michael Benatar MD PhD, Thomas Hansen PhD, Dror Rom PhD, Marie A Geist PhD, Thomas Blaettler MD, Prof William Camu MD PhD, Prof Magdalena Kuzma-Kozakiewicz MD PhD, Prof Leonard H van den Berg MD PhD, Raul Juntas Morales MD PhD, Prof Adriano Chio MD, Prof Peter M Andersen MD PhD, Pierre-Francois Pradat MD PhD, Dale Lange MD, Prof Philip Van Damme MD PhD, Gabriele Mora MD, Mariusz Grudniak PhD,
Amyotrophic lateral sclerosis is a progressive neurodegenerative disorder leading to muscle weakness and respiratory failure. Arimoclomol, a heat-shock protein-70 (HSP70) co-inducer, is neuroprotective in animal models of amyotrophic lateral sclerosis, with multiple mechanisms of action, including clearance of protein aggregates, a pathological hallmark of sporadic and familial amyotrophic lateral
-
Progress in physical therapy for functional motor disorder Lancet Neurol. (IF 46.5) Pub Date : 2024-05-17 Mark Hallett
-
Specialist physiotherapy for functional motor disorder in England and Scotland (Physio4FMD): a pragmatic, multicentre, phase 3 randomised controlled trial Lancet Neurol. (IF 46.5) Pub Date : 2024-05-17 Glenn Nielsen PhD, Prof Jon Stone PhD, Teresa C Lee MSc, Prof Laura H Goldstein PhD, Prof Louise Marston PhD, Prof Rachael Maree Hunter MSc, Prof Alan Carson MD, Kate Holt BSc, Prof Jon Marsden PhD, Marie Le Novere MSc, Prof Irwin Nazareth PhD, Hayley Noble MMedSci, Prof Markus Reuber PhD, Ann-Marie Strudwick MSc, Beatriz Santana Suarez BSc, Prof Mark J Edwards PhD, Physio4FMD study group, Emily Beaves
Functional motor disorder—the motor variant of functional neurological disorder—is a disabling condition that is commonly associated with poor health outcomes. Pathophysiological models have inspired new treatment approaches such as specialist physiotherapy, although evidence from large randomised controlled trials is absent. We aimed to assess the clinical effectiveness of a specialist physiotherapy
-
Challenging the management of blood pressure before intravenous thrombolysis in acute ischaemic stroke Lancet Neurol. (IF 46.5) Pub Date : 2024-05-16 Verónica V Olavarría
-
Safety and efficacy of active blood-pressure reduction to the recommended thresholds for intravenous thrombolysis in patients with acute ischaemic stroke in the Netherlands (TRUTH): a prospective, observational, cluster-based, parallel-group study Lancet Neurol. (IF 46.5) Pub Date : 2024-05-16 Thomas P Zonneveld MD, Sarah E Vermeer MD PhD, Erik W van Zwet MD PhD, Adrien E D Groot MD PhD, Prof Ale Algra MD PhD, Leo A M Aerden MD PhD, Kees C L Alblas MD, Frank de Beer MD, Paul J A M Brouwers MD PhD, Koen de Gans MD, H Maarten A van Gemert MD, Bart C A M van Ginneken MD, Gerke S Grooters MD, Patricia H A Halkes MD PhD, Tonny A M H G van der Heijden-Montfroy MD, Korné Jellema MD PhD, Sonja W
Intravenous thrombolysis is contraindicated in patients with ischaemic stroke with blood pressure higher than 185/110 mm Hg. Prevailing guidelines recommend to actively lower blood pressure with intravenous antihypertensive agents to allow for thrombolysis; however, there is no robust evidence for this strategy. Because rapid declines in blood pressure can also adversely affect clinical outcomes, several
-
Angela Vincent: a pioneer of immune-mediated disease Lancet Neurol. (IF 46.5) Pub Date : 2024-03-20 Jules Morgan
-
Increasing awareness of the need for brain health Lancet Neurol. (IF 46.5) Pub Date : 2024-03-18 The Lancet Neurology
-
Getting inside the head of Edinburgh Fringe performers Lancet Neurol. (IF 46.5) Pub Date : 2024-03-18 Peter Ranscombe
-
-
Cristina Tassorelli: making a difference in headache research Lancet Neurol. (IF 46.5) Pub Date : 2024-03-18 Udani Samarasekera
-
Detection of atrial fibrillation in patients after stroke – Authors' reply Lancet Neurol. (IF 46.5) Pub Date : 2024-03-18 Luciano A Sposato, Jason G Andrade, Thalia S Field
-
New therapeutic avenues for Duchenne muscular dystrophy Lancet Neurol. (IF 46.5) Pub Date : 2024-03-18 Janbernd Kirschner
-
Pragmatic solutions for the global burden of stroke – Authors' reply Lancet Neurol. (IF 46.5) Pub Date : 2024-03-18 Valery L Feigin, Joseph Yaria, Mayowa Owolabi
-
Implications of the KIWE trial for low-income and lower-middle-income countries – Authors' reply Lancet Neurol. (IF 46.5) Pub Date : 2024-03-18 J Helen Cross, Natasha E Schoeler, Louise Marston, Nick Freemantle, KIWE investigators
-
-
Implications of the KIWE trial for low-income and lower-middle-income countries Lancet Neurol. (IF 46.5) Pub Date : 2024-03-18 Jitendra Kumar Sahu, Priyanka Madaan, Jithangi Wanigasinghe, Pauline Samia, South Asia allied IESS Research Group, Aye Mya Min Aye, Esmatullah Hamed, Kanij Fatema, Kyaw Linn, Mimi L Mynak, Nicolás Garófalo Gómez, Prakash Poudel, Prem Chand, Samaahath Hassan
-
Dysphagia after stroke: research advances in treatment interventions Lancet Neurol. (IF 46.5) Pub Date : 2024-03-18 Bendix Labeit MD, Emilia Michou PhD, Michaela Trapl-Grundschober PhDr, Prof Sonja Suntrup-Krueger MD, Paul Muhle MD, Prof Philip M Bath FMedSci, Rainer Dziewas MD
After a stroke, most patients have dysphagia, which can lead to aspiration pneumonia, malnutrition, and adverse functional outcomes. Protective interventions aimed at reducing these complications remain the cornerstone of treatment. Dietary adjustments and oral hygiene help mitigate the risk of aspiration pneumonia, and nutritional supplementation, including tube feeding, might be needed to prevent
-
Detection of atrial fibrillation in patients after stroke Lancet Neurol. (IF 46.5) Pub Date : 2024-03-18 Konstantinos C Siontis, Peter A Noseworthy, Paul A Friedman
-
Pragmatic solutions for the global burden of stroke Lancet Neurol. (IF 46.5) Pub Date : 2024-03-18 Mathias Schlögl, Terence J Quinn, International Stroke Recovery and Rehabilitation Alliance (SRRRA) Frailty Stroke Group
-
Pragmatic solutions for the global burden of stroke Lancet Neurol. (IF 46.5) Pub Date : 2024-03-18 Amit Kandel, Amit Arjyal, Biraj Karmacharya, Bikram Gajurel
-
Secondary stroke prevention in people with atrial fibrillation: treatments and trials Lancet Neurol. (IF 46.5) Pub Date : 2024-03-18 Prof David J Seiffge MD, Virginia Cancelloni MD, Prof Lorenz Räber PhD, Maurizio Paciaroni MD, Prof Andreas Metzner MD, Prof Paulus Kirchhof MD FRCP, Prof Urs Fischer MD, Prof David J Werring PhD FRCP, Prof Ashkan Shoamanesh MD FRCPC, Prof Valeria Caso MD
Atrial fibrillation is one of the most common cardiac arrhythmias and is a major cause of ischaemic stroke. Recent findings indicate the importance of atrial fibrillation burden (device-detected, subclinical, or paroxysmal and persistent or permanent) and whether atrial fibrillation was known before stroke onset or diagnosed after stroke for the risk of recurrence. Secondary prevention in patients
-
Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Lancet Neurol. (IF 46.5) Pub Date : 2024-03-18 Prof Eugenio Mercuri MD, Prof Juan J Vilchez MD, Prof Odile Boespflug-Tanguy MD, Craig M Zaidman MD, Prof Jean K Mah MD, Nathalie Goemans MD, Prof Wolfgang Müller-Felber MD, Erik H Niks MD, Prof Ulrike Schara-Schmidt MD, Enrico Bertini MD, Prof Giacomo P Comi MD, Prof Katherine D Mathews MD, Prof Laurent Servais MD, Krista Vandenborne PhD, Jessika Johannsen MD, Prof Sonia Messina MD, Stefan Spinty
Duchenne muscular dystrophy, the most common childhood muscular dystrophy, is caused by dystrophin deficiency. Preclinical and phase 2 study data have suggested that givinostat, a histone deacetylase inhibitor, might help to counteract the effects of this deficiency. We aimed to evaluate the safety and efficacy of givinostat in the treatment of Duchenne muscular dystrophy. This multicentre, randomised
-
Genetics of migraine: complexity, implications, and potential clinical applications Lancet Neurol. (IF 46.5) Pub Date : 2024-03-18 Heidi G Sutherland PhD, Bronwyn Jenkins BMed, Prof Lyn R Griffiths PhD
Migraine is a common neurological disorder with large burden in terms of disability for individuals and costs for society. Accurate diagnosis and effective treatments remain priorities. Understanding the genetic factors that contribute to migraine risk and symptom manifestation could improve individual management. Migraine has a strong genetic basis that includes both monogenic and polygenic forms
-
Fluctuations in Parkinson's disease: progress and challenges Lancet Neurol. (IF 46.5) Pub Date : 2024-03-15 Francisco Cardoso, Eduardo Tolosa
-
Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial Lancet Neurol. (IF 46.5) Pub Date : 2024-03-15 Prof Alberto J Espay MD, Prof Fabrizio Stocchi MD, Prof Rajesh Pahwa MD, Prof Alberto Albanese MD, Aaron Ellenbogen MD, Prof Joaquim J Ferreira MD, Prof Nir Giladi MD, Tanya Gurevich MD, Sharon Hassin-Baer MD, Jorge Hernandez-Vara MD, Stuart H Isaacson MD, Prof Karl Kieburtz MD, Prof Peter A LeWitt MD, Lydia Lopez-Manzanares MD, Prof C Warren Olanow MD, Prof Werner Poewe MD, Harini Sarva MD, Tami Yardeni
Conventional oral levodopa therapy for the treatment of Parkinson's disease can be associated with variations in plasma concentrations. Levodopa infusion strategies might provide more consistent drug delivery and fewer motor fluctuations. We aimed to assess the safety and efficacy of a continuous 24 h/day subcutaneous infusion of ND0612 (a levodopa–carbidopa solution) compared with oral immediate-release
-
The expanding burden of neurological disorders Lancet Neurol. (IF 46.5) Pub Date : 2024-03-14 Wolfgang Grisold
-
Addressing neurological burden in the Americas Lancet Neurol. (IF 46.5) Pub Date : 2024-03-14 Amy Tausch, Kiran T Thakur, Renato Oliveira e Souza
-
Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 Lancet Neurol. (IF 46.5) Pub Date : 2024-03-14 GBD 2021 Nervous System Disorders Collaborators, Jaimie D Steinmetz, Katrin Maria Seeher, Nicoline Schiess, Emma Nichols, Bochen Cao, Chiara Servili, Vanessa Cavallera, Ewerton Cousin, Hailey Hagins, Madeline E Moberg, Max L Mehlman, Yohannes Habtegiorgis Abate, Jaffar Abbas, Madineh Akram Abbasi, Mohammadreza Abbasian, Hedayat Abbastabar, Michael Abdelmasseh, Mohammad Abdollahi, Mozhan Abdollahi,
-
-
-
Potential treatment targets for migraine: emerging options and future prospects Lancet Neurol. (IF 46.5) Pub Date : 2024-02-15 Chia-Chun Chiang, Frank Porreca, Carrie E Robertson, David W Dodick
-
Sleep matters in anti-LGI1 encephalitis Lancet Neurol. (IF 46.5) Pub Date : 2024-02-15 Anna Heidbreder
-
Neurological, psychiatric, and sleep investigations after treatment of anti-leucine-rich glioma-inactivated protein 1 (LGI1) encephalitis in Spain: a prospective cohort study Lancet Neurol. (IF 46.5) Pub Date : 2024-02-15 Amaia Muñoz-Lopetegi, Mar Guasp, Laia Prades, Eugenia Martínez-Hernández, Mireia Rosa-Justícia, Víctor Patricio, Thaís Armangué, Lorena Rami, Roger Borràs, Josefina Castro-Fornieles, Albert Compte, Carles Gaig, Joan Santamaria, Josep Dalmau
-
-
-
Thank you to The Lancet Neurology's peer reviewers in 2023 Lancet Neurol. (IF 46.5) Pub Date : 2024-02-15
-
For a dementia diagnosis, clinical acumen must precede biomarkers Lancet Neurol. (IF 46.5) Pub Date : 2024-02-15 David S Knopman
-
The predictive value and clinical use of the neurological pupillary index Lancet Neurol. (IF 46.5) Pub Date : 2024-02-15 Michael TC Poon, Ahmed Nouby, Paul M Brennan
-
Biomedical research must change as the climate does Lancet Neurol. (IF 46.5) Pub Date : 2024-02-15 Grace Lindsay
-
The cultural history of dementia Lancet Neurol. (IF 46.5) Pub Date : 2024-02-15 Hollie Sherwood-Martin
-
Monitoring patients with severe traumatic brain injury Lancet Neurol. (IF 46.5) Pub Date : 2024-02-15 Ramon Diaz-Arrastia, Francis Bernard, Lori Shutter, William Barsan, Robert Silbergleit
-
Monitoring patients with severe traumatic brain injury Lancet Neurol. (IF 46.5) Pub Date : 2024-02-15 Randall M Chesnut, Robert H Bonow, Walter Videtta
-
Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges Lancet Neurol. (IF 46.5) Pub Date : 2024-02-15 Jeremy Chataway, Thomas Williams, Vivien Li, Ruth Ann Marrie, Daniel Ontaneda, Robert J Fox
-
Monitoring patients with severe traumatic brain injury Lancet Neurol. (IF 46.5) Pub Date : 2024-02-15 Nathan Beucler
-
-
-
A future treatment horizon for migraine? Lancet Neurol. (IF 46.5) Pub Date : 2024-02-15 Debbie L Hay
-
-
Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study Lancet Neurol. (IF 46.5) Pub Date : 2024-02-15 Pushpa Narayanaswami, Donald B Sanders, Laine Thomas, Dylan Thibault, Jason Blevins, Rishi Desai, Andrew Krueger, Kathie Bibeau, Bo Liu, Jeffrey T Guptill, Vern C. Juel, Karissa L. Gable, Lisa D. Hobson-Webb, Janice M. Massey, Shruti Raja, C. Douglas Emmet, Yuebing Li, David Polston, Steven Shook, Debbie Hastings, Zaeem A. Siddiqi, Muhammed Abid Alvi, Haley Andonian, Michael Nicolle, Denise Hulley